Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Teodora A Todorova, Stanislav H Jordanov, Gergana S Stancheva, Ivan J Chalakov, Mincho B Melnicharov, Kuncho V Kunev, Vanio I Mitev, Radka P Kaneva, Teodora E Goranova
Author Information
  1. Teodora A Todorova: Molecular Medicine Center, Medical University-Sofia, 2 Zdrave street, Sofia, 1431, Bulgaria.

Abstract

Laryngeal squamous cell carcinoma (LSCC) is the second most common tumour of the head and neck. It is characterized by frequent aberrations in two cell-cycle regulators--CDKN2A and TP53. However, LSCC has been often studied as a part of the group of head and neck cancers and not as an individual entity. In the current study we aimed to examine mutation status of CDKN2A and TP53 genes in 108 LSCC patients. DNA was extracted from fresh-frozen tumour tissues; exons 1-3 of CDKN2A and exons 5-8 of TP53 were screened for mutations by direct sequencing. Genetic aberrations in CDKN2A were found in 16 (14.2%) and those in TP53--in 56/108 (51.9%) tumours. Seven mutations (two insertions, three deletions, one missense and one silent) detected in CDKN2A were not described previously. Also, we found seven novel deletions and a novel indel in TP53. No significant associations with clinical features were found. However, TP53 mutations were predominantly observed in smokers with advanced stage tumours. Screening for genetic aberrations in a defined group of LSCC contributes to the knowledge about laryngeal carcinogenesis. Further investigations are required to confirm the observed trends in associations with clinical features.

References

  1. Int J Cancer. 1995 Mar 16;60(6):786-90 [PMID: 7896446]
  2. Nat Genet. 1994 Sep;8(1):27-32 [PMID: 7726912]
  3. Cancer Cell. 2007 Nov;12(5):414-8 [PMID: 17996645]
  4. Science. 2011 Aug 26;333(6046):1154-7 [PMID: 21798897]
  5. PLoS One. 2012;7(2):e30921 [PMID: 22319594]
  6. Mol Biol Rep. 2010 Jan;37(1):325-32 [PMID: 19690981]
  7. Nat Rev Cancer. 2009 Oct;9(10):691-700 [PMID: 19759539]
  8. Nat Genet. 1999 Jan;21(1):128-32 [PMID: 9916806]
  9. Carcinogenesis. 2002 Mar;23(3):419-24 [PMID: 11895856]
  10. Science. 1990 Nov 30;250(4985):1233-8 [PMID: 1978757]
  11. Cell Death Differ. 2010 Feb;17(2):193-9 [PMID: 19461653]
  12. J Pathol. 2002 Dec;198(4):476-86 [PMID: 12434417]
  13. PLoS One. 2013 Nov 20;8(11):e80828 [PMID: 24278325]
  14. Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [PMID: 15187189]
  15. Cancer Res. 1994 Oct 15;54(20):5269-72 [PMID: 7923152]
  16. Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [PMID: 17692090]
  17. Nature. 2009 Jul 23;460(7254):529-33 [PMID: 19626115]
  18. Gastroenterology. 1992 Sep;103(3):892-6 [PMID: 1499939]
  19. Jpn J Cancer Res. 1992 Oct;83(10):1030-6 [PMID: 1333465]
  20. Cancer Res. 1994 Mar 1;54(5):1298-304 [PMID: 8118819]
  21. Nat Rev Cancer. 2012 Sep;12(9):613-26 [PMID: 22898542]
  22. Cancer Res. 1997 May 15;57(10):1895-902 [PMID: 9157982]
  23. Cancer Res. 2005 Feb 1;65(3):835-9 [PMID: 15705881]
  24. Cancer. 2007 Aug 1;110(3):694-702 [PMID: 17567834]
  25. J Natl Cancer Inst. 1994 Mar 2;86(5):344-9 [PMID: 8308926]
  26. Cancer Res. 1992 Nov 1;52(21):6098-100 [PMID: 1327523]
  27. Br J Cancer. 1993 Sep;68(3):540-8 [PMID: 8102535]
  28. Nat Rev Cancer. 2011 Jan;11(1):9-22 [PMID: 21160525]
  29. N Engl J Med. 1995 Mar 16;332(11):712-7 [PMID: 7854378]
  30. Am J Hum Genet. 2003 Apr;72(4):975-83 [PMID: 12610779]
  31. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8241-6 [PMID: 22493262]
  32. Clin Cancer Res. 2001 Jun;7(6):1523-32 [PMID: 11410486]
  33. Cancer Res. 1996 Jun 1;56(11):2488-92 [PMID: 8653682]
  34. Head Neck. 2005 Aug;27(8):653-8 [PMID: 16035097]
  35. Oncogene. 2007 Apr 2;26(15):2145-56 [PMID: 17401423]
  36. Cancer Res. 1993 May 1;53(9):2128-32 [PMID: 8481915]
  37. J Clin Oncol. 2000 Apr;18(7):1465-73 [PMID: 10735894]
  38. Nature. 1977 Feb 24;265(5596):687-95 [PMID: 870828]
  39. Int J Oncol. 1999 Sep;15(3):547-53 [PMID: 10427138]
  40. Ann Oncol. 2006 Jun;17 Suppl 7:vii137-41 [PMID: 16760277]
  41. Int J Cancer. 1999 May 31;81(5):705-11 [PMID: 10328220]
  42. Ann Oncol. 2014 Oct;25(10):1889-1900 [PMID: 24718888]
  43. Science. 1994 Jul 15;265(5170):346-55 [PMID: 8023157]
  44. Cancer Res. 2000 Dec 15;60(24):6788-93 [PMID: 11156366]
  45. Cancer Res. 1993 Oct 1;53(19):4477-80 [PMID: 8402617]
  46. Int J Oral Maxillofac Surg. 2007 Dec;36(12):1123-38 [PMID: 17875383]
  47. Head Neck. 2014 Aug;36(8):1103-8 [PMID: 23804521]
  48. N Engl J Med. 2007 Dec 20;357(25):2552-61 [PMID: 18094376]
  49. Cancer Res. 1992 Sep 15;52(18):5119-22 [PMID: 1516069]
  50. Mol Carcinog. 2004 Mar;39(3):147-54 [PMID: 14991744]
  51. Am J Hum Genet. 1995 Mar;56(3):608-15 [PMID: 7887414]
  52. Cancer Res. 1995 Aug 1;55(15):3406-11 [PMID: 7614480]
  53. Eur J Cancer. 2004 Nov;40(16):2383-8 [PMID: 15519509]
  54. Exp Cell Res. 2001 Mar 10;264(1):42-55 [PMID: 11237522]
  55. Cell. 1997 Nov 28;91(5):649-59 [PMID: 9393858]
  56. Int J Cancer. 1996 Aug 22;69(4):259-64 [PMID: 8797864]
  57. J Clin Pathol. 2006 May;59(5):445-53 [PMID: 16644882]
  58. Nat Chem Biol. 2011 May;7(5):285-95 [PMID: 21445056]
  59. Cancer Genet Cytogenet. 2003 Oct 1;146(1):8-15 [PMID: 14499690]
  60. Oncology. 2001;60(2):176-88 [PMID: 11244334]
  61. Cancer Res. 1992 Nov 15;52(22):6400-3 [PMID: 1423288]
  62. Cancer Res. 2003 Mar 15;63(6):1188-91 [PMID: 12649174]
  63. Cancer Control. 2002 Sep-Oct;9(5):369-78 [PMID: 12410176]
  64. Oncogene. 1997 Oct 2;15(14):1737-40 [PMID: 9349508]
  65. Cancer Res. 1994 Mar 1;54(5):1156-8 [PMID: 8118798]
  66. Br J Cancer. 2000 Jun;82(12):1932-7 [PMID: 10864200]
  67. Eur J Cancer. 2007 Jan;43(1):137-43 [PMID: 17055252]
  68. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14338-42 [PMID: 9405613]
  69. Nature. 1994 Apr 21;368(6473):753-6 [PMID: 8152487]
  70. Cancer Res. 1994 Oct 1;54(19):5050-3 [PMID: 7923115]
  71. N Engl J Med. 1992 May 14;326(20):1301-8 [PMID: 1565143]
  72. Oncogene. 1995 Nov 2;11(9):1843-51 [PMID: 7478613]
  73. J Invest Dermatol. 2004 Jan;122(1):190-200 [PMID: 14962108]
  74. Cancer Res. 1993 Jan 15;53(2):368-72 [PMID: 8093350]
  75. J Clin Oncol. 1994 May;12(5):925-30 [PMID: 8164043]
  76. Cancer Genet Cytogenet. 1999 Jul 1;112(1):26-33 [PMID: 10432931]
  77. Pediatr Neurosurg. 2008;44(6):501-8 [PMID: 19127094]
  78. Oncogene. 1994 Apr;9(4):1231-5 [PMID: 8134126]
  79. Int J Cancer. 2004 Nov 20;112(4):545-53 [PMID: 15382034]
  80. Int J Cancer. 2004 Sep 10;111(4):530-8 [PMID: 15239130]
  81. Otolaryngol Clin North Am. 2008 Aug;41(4):657-72, v [PMID: 18570952]
  82. Cancer Res. 1997 Aug 1;57(15):3245-52 [PMID: 9242456]
  83. Nature. 2000 Nov 16;408(6810):307-10 [PMID: 11099028]
  84. Nat Rev Cancer. 2009 Oct;9(10):724-37 [PMID: 19776742]
  85. Am J Pathol. 1998 Apr;152(4):1057-63 [PMID: 9546366]
  86. Hum Mutat. 2003 Mar;21(3):252-7 [PMID: 12619110]
  87. J Clin Invest. 1995 Apr;95(4):1606-11 [PMID: 7706467]

MeSH Term

Carcinoma, Squamous Cell
Cyclin-Dependent Kinase Inhibitor p16
DNA, Neoplasm
Female
Genes, Neoplasm
Head and Neck Neoplasms
Humans
Laryngeal Neoplasms
Male
Middle Aged
Mutation
Prognosis
Sequence Analysis, DNA
Tumor Suppressor Protein p53

Chemicals

Cyclin-Dependent Kinase Inhibitor p16
DNA, Neoplasm
TP53 protein, human
Tumor Suppressor Protein p53

Word Cloud

Created with Highcharts 10.0.0TP53CDKN2ALSCCaberrationsmutationsfoundLaryngealtumourheadnecktwoHowevergroupexonstumoursdeletionsonenovelassociationsclinicalfeaturesobservedsquamouscellcarcinomasecondcommoncharacterizedfrequentcell-cycleregulators--CDKN2Aoftenstudiedpartcancersindividualentitycurrentstudyaimedexaminemutationstatusgenes108patientsDNAextractedfresh-frozentissues1-35-8screeneddirectsequencingGenetic16142%TP53--in56/108519%SeveninsertionsthreemissensesilentdetecteddescribedpreviouslyAlsosevenindelsignificantpredominantlysmokersadvancedstageScreeninggeneticdefinedcontributesknowledgelaryngealcarcinogenesisinvestigationsrequiredconfirmtrendsMutationalStatusGenesSquamousCellCarcinoma

Similar Articles

Cited By